Shares of Coloplast A/S Sponsored ADR (OTCMKTS:CLPBY – Get Free Report) gapped up before the market opened on Monday . The stock had previously closed at $6.88, but opened at $7.16. Coloplast A/S shares last traded at $7.19, with a volume of 11,728 shares trading hands.
Wall Street Analysts Forecast Growth
Separately, Kepler Capital Markets raised Coloplast A/S to a “strong-buy” rating in a research note on Wednesday, May 20th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Coloplast A/S presently has an average rating of “Hold”.
Get Our Latest Analysis on Coloplast A/S
Coloplast A/S Trading Up 5.2%
Coloplast A/S (OTCMKTS:CLPBY – Get Free Report) last posted its quarterly earnings results on Tuesday, August 18th. The company reported $0.10 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.10. The company had revenue of $1.14 billion during the quarter, compared to the consensus estimate of $1.11 billion. Coloplast A/S had a return on equity of 38.81% and a net margin of 9.68%. Research analysts expect that Coloplast A/S Sponsored ADR will post 0.39 EPS for the current fiscal year.
About Coloplast A/S
Coloplast A/S is a global developer and manufacturer of medical devices and services focused on intimate healthcare. The company specializes in solutions designed to assist individuals with chronic medical conditions, aiming to improve quality of life through innovative products. Coloplast’s offerings span ostomy care, continence care, wound and skin care, and interventional urology, targeting patients who require long-term support and specialized treatments.
In its ostomy business, Coloplast provides pouches, skin barriers and accessories for patients who have had surgical procedures to divert bodily waste.
Recommended Stories
- Five stocks we like better than Coloplast A/S
- MongoDB Is Surging—And the Next Catalyst Is Almost Here
- If Boeing Ramps Up Production, These Suppliers May Win Big
- Marvell Takes a Shot a Broadcom’s Throne With Google Deal
- 5 of the Most-Upgraded Stocks Over the Last Quarter Are All Software Names—Here’s Why
Receive News & Ratings for Coloplast A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coloplast A/S and related companies with MarketBeat.com's FREE daily email newsletter.
